MA33351B1 - Formes stables du n-(2,6-diméthyl-4-morpholin-4-ylphényl)-3,3-diméthylbutyramide - Google Patents

Formes stables du n-(2,6-diméthyl-4-morpholin-4-ylphényl)-3,3-diméthylbutyramide

Info

Publication number
MA33351B1
MA33351B1 MA34435A MA34435A MA33351B1 MA 33351 B1 MA33351 B1 MA 33351B1 MA 34435 A MA34435 A MA 34435A MA 34435 A MA34435 A MA 34435A MA 33351 B1 MA33351 B1 MA 33351B1
Authority
MA
Morocco
Prior art keywords
dimethyl
morpholine
phenyl
stable form
dimethylbutyramide
Prior art date
Application number
MA34435A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Svend Treppendahl
Karin Liltorp
De Diego Heidi Lopez
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42237259&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33351(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of MA33351B1 publication Critical patent/MA33351B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
MA34435A 2009-05-11 2010-05-11 Formes stables du n-(2,6-diméthyl-4-morpholin-4-ylphényl)-3,3-diméthylbutyramide MA33351B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200900597 2009-05-11
PCT/DK2010/050101 WO2010130260A2 (en) 2009-05-11 2010-05-11 Stable forms of n-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide

Publications (1)

Publication Number Publication Date
MA33351B1 true MA33351B1 (fr) 2012-06-01

Family

ID=42237259

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34435A MA33351B1 (fr) 2009-05-11 2010-05-11 Formes stables du n-(2,6-diméthyl-4-morpholin-4-ylphényl)-3,3-diméthylbutyramide

Country Status (23)

Country Link
EP (1) EP2430008A2 (zh)
JP (1) JP2012526152A (zh)
KR (1) KR20120022934A (zh)
CN (1) CN102459208A (zh)
AR (1) AR076556A1 (zh)
AU (1) AU2010246724B2 (zh)
BR (1) BRPI1013930A2 (zh)
CA (1) CA2761383A1 (zh)
CL (1) CL2011002814A1 (zh)
CO (1) CO6460741A2 (zh)
CR (1) CR20110590A (zh)
DO (1) DOP2011000351A (zh)
EA (1) EA201171381A1 (zh)
GE (1) GEP20146006B (zh)
IL (1) IL216148A0 (zh)
MA (1) MA33351B1 (zh)
MX (1) MX2011011885A (zh)
NZ (1) NZ596738A (zh)
SG (1) SG175968A1 (zh)
TN (1) TN2011000557A1 (zh)
TW (1) TW201041857A (zh)
WO (1) WO2010130260A2 (zh)
ZA (1) ZA201108112B (zh)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI349666B (en) * 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
MX2009002002A (es) * 2006-08-23 2009-07-22 Valeant Pharmaceuticals Int Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potasio.
CA2694887A1 (en) * 2007-08-01 2009-02-05 Henriette Husum Bak-Jensen Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted

Also Published As

Publication number Publication date
JP2012526152A (ja) 2012-10-25
AU2010246724B2 (en) 2013-03-21
TN2011000557A1 (en) 2013-05-24
CL2011002814A1 (es) 2012-04-13
IL216148A0 (en) 2012-01-31
AR076556A1 (es) 2011-06-22
SG175968A1 (en) 2011-12-29
WO2010130260A2 (en) 2010-11-18
MX2011011885A (es) 2011-12-06
WO2010130260A9 (en) 2012-10-18
BRPI1013930A2 (pt) 2019-09-24
WO2010130260A3 (en) 2011-06-16
TW201041857A (en) 2010-12-01
DOP2011000351A (es) 2012-01-31
EP2430008A2 (en) 2012-03-21
NZ596738A (en) 2013-04-26
CR20110590A (es) 2012-02-22
GEP20146006B (en) 2014-01-10
CA2761383A1 (en) 2010-11-18
EA201171381A1 (ru) 2012-05-30
CN102459208A (zh) 2012-05-16
CO6460741A2 (es) 2012-06-15
AU2010246724A1 (en) 2011-12-08
KR20120022934A (ko) 2012-03-12
ZA201108112B (en) 2013-01-30

Similar Documents

Publication Publication Date Title
NI200700160A (es) Formas cristalinas del hidrocloruro de (r)-8-cloro-1-metil-2,3,4,5-tetrahidro-1h-3-benzazepina
TW200736247A (en) Compounds for the treatment of inflammatory disorders
DK2824183T3 (da) Fremgangsmåde til fremstilling af bispecifikke antistoffer
EA200800549A1 (ru) Региоселективный способ получения бензимидазолтиофенов
GT200500296A (es) Sintesis asimetrica de derivados del dehidrobenzofurano
MA32977B1 (fr) Formes polymorphiques du (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo(c(1,2)oxaborol-1-ol
PL380915A1 (pl) Sposób wytwarzania azotkowego podłoża półprzewodnikowego oraz azotkowe podłoże półprzewodnikowe
IT1392456B1 (it) Processo per la sintesi di di- o oligosaccaridi l-fucosilati e loro nuovi intermedi 2,3,4-tribenzil-fucosil-derivati.
BRPI0710199A2 (pt) Processo para preparação de inibidores de hiv protease
DK2082054T3 (da) Fremgangsmåde til forbedring af udbyttet af celluloseomdannelsesprocesser
MY146084A (en) Benzyl amines, a process for their production and their use as anti-inflammatory agents
TW200728310A (en) Process for the preparation of ferri-succinylcasein
NO20071254L (no) Fremgangsmate for fremstilling av irbesartan og mellomprodukter derav.
EA200870038A1 (ru) Способ получения аминов
BRPI0914400A2 (pt) "processo para a síntese de um composto"
MY148880A (en) N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression
FR2950880B1 (fr) Procede de preparation d'anhydrite pour la fabrication d'un mortier
HN2009001437A (es) Nueva procedimiento de obtencion de la forma cristalina v de la agomelatina
MA29092B1 (fr) Procédé de synthèse de salicylamides n-substitués
MA33351B1 (fr) Formes stables du n-(2,6-diméthyl-4-morpholin-4-ylphényl)-3,3-diméthylbutyramide
BRPI0914350A2 (pt) "processo para a síntese de um composto"
MC200131A1 (fr) Procédé et installation pour la fabrication d'un liant sulfatique à hautes résistances mécaniques précoces, resistant à l'eau et le liant ainsi obtenu
ZA201001694B (en) Process for the manufacture of bridged monobactam intermediates
GB0713566D0 (en) The Synthesis of,N-alkylbis(orciny)phenox AZinones;N-alkyl 3,6-D1(1'3'-Dihydroxy-5'-methylbenzene 6')4,5-Dimethylphenoxazin-2-one-7-oxides
FI20051058A0 (fi) Menetelmä puhtaiden enantiomeerien valmistukseen